Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
- Author:
Jang Ho LEE
1
;
Eun Young KIM
;
Cheol-Kyu PARK
;
Shin Yup LEE
;
Min ki LEE
;
Seong-Hoon YOON
;
Jeong Eun LEE
;
Sang Hoon LEE
;
Seung Joon KIM
;
Sung Yong LEE
;
Jun Hyeok LIM
;
Tae-Won JANG
;
Seung Hun JANG
;
Kye Young LEE
;
Seung Hyeun LEE
;
Sei Hoon YANG
;
Dong Won PARK
;
Chan Kwon PARK
;
Hye Seon KANG
;
Chang Dong YEO
;
Chang-Min CHOI
;
Jae Cheol LEE
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(1):112-122
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.
Materials and Methods:Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.
Results:A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.
Conclusion:Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.
